Company Overview and News

 
Vedanta rises 5% on gas discovery in KG basin

2018-09-14 moneycontrol
Shares of Vedanta rose 5 percent intraday Friday after company announced hydrocarbon discovery in well A3-2 within its operated block KG-OSN-2009/3 within Krishna-Godavari Basin, East Coast of India.
532792 CAIRN CWNQY

4
Tata Petrodyne may be sold to Invenire Energy

2018-09-12 livemint
Mumbai: Invenire Energy Pvt. Ltd will likely acquire Tata Petrodyne Ltd (), the upstream oil and gas business of the diversified Tata Group, said three people aware of the matter. Invenire Energy is backed by a consortium of private equity firms for the potential deal, the people who didn’t wish to be named said in an interview. The transaction is expected to close shortly, they said without disclosing the estimated value of the deal.
TATAPOWER CAIRN CWNQY 500470 HINDOILEXP TTST 532792 TATASTEEL TATLY TPCL 500400 500570 TATAMOTORS 500186 TTM

 
Final hearing in Cairn arbitration against retro tax to begin Monday

2018-08-19 moneycontrol
The final hearing in British oil firm Cairn Energy Plc's challenge to India imposing a Rs 10,247 crore retrospective tax demand will begin in The Hague tomorrow, people familiar with the matter said.
CNE 532792 CRNZF VEDL CAIRN CWNQY CRNCY

 
Vedanta set to bag 40 oil blocks, ONGC 2, HOEC 1

2018-08-07 livemint
New Delhi: Anil Agarwal-led Vedanta Ltd is likely to bag as many as 40 oil and gas exploration blocks in India’s maiden open acreage auction, people familiar with the matter said on Tuesday.
HINDOILEXP 532792 500325 RELIANCE RIGD 500186 CAIRN CWNQY RLNIY

 
Vedanta set to bag 40 oil blocks, ONGC 2, HOEC 1

2018-08-07 moneycontrol
Anil Agarwal-led Vedanta Ltd is likely to bag as many as 40 oil and gas exploration blocks in India's maiden open acreage auction, official sources said today. An Empowered Committee of Secretaries (ECS) has cleared award of blocks offered in OALP-1, bidding for which closed on May 2, they said.
HINDOILEXP 532792 500325 RELIANCE RIGD 500186 CAIRN CWNQY RLNIY

 
Cairn Energy says I-T department sells $216 million of Vedanta shares

2018-07-09 livemint
New Delhi: Cairn Energy Plc said on Monday the income tax department had sold about $216 million worth of Vedanta Ltd shares owned by Cairn in connection with the recovery of a part of a Rs 10,247 crore retrospective tax demand.
CNE 532792 CRNZF VEDL CAIRN CWNQY CRNCY

 
[Press] Update on Cairn’s Assets in India

2018-07-09 oilvoice
Cairn is providing an update on its ongoing arbitration with the Government of India under the UK-India Bilateral Investment Treaty (“the Treaty”).
532792 VEDL CAIRN CWNQY

 
Vedanta delisting not related to Tuticorin incident: Anil Agarwal

2018-07-03 moneycontrol
Mining mogul Anil Agarwal today said his plan to delist his flagship Vedanta Resources Plc from London Stock Exchange and take it private is no way linked to the Tuticorin incident and is merely an exercise to simplify a sprawling business empire. Agarwal, who launched a USD 1 billion offer to buy the 33.65 percent stake of Vedanta that his family trust does not own, while on a cruise with family in the Mediterranean, said the liquidity of Indian markets now means that the need for a separate London listing is no longer critical.
VED 532792 DTK LNSTY HNDZY VEDL CAIRN CWNQY 500188 HINDZINC

 
Vedanta Resources delisting not related to Tuticorin incident, says Anil Agarwal

2018-07-03 livemint
New Delhi: Mining mogul Anil Agarwal on Tuesday said that his plan to delist his flagship Vedanta Resources Plc from London Stock Exchange and take it private is no way linked to the Tuticorin incident and is merely an exercise to simplify a sprawling business empire.
VED 532792 DTK LNSTY HNDZY VEDL CAIRN CWNQY 500188 HINDZINC

2
Vedanta to be de-listed as boss Agarwal launches bid to take full ownership of Indian miner

2018-07-02 telegraph.co.uk - 1
The billionaire executive chairman and controlling shareholder of mining group Vedanta Resources has launched a bid to take full control of the company that will result in it ditching its London listing.
VED 532792 LNSTY VEDL CAIRN CWNQY

 
Managing externalities: The case of Sterilite

2018-06-02 freepressjournal.in
Businessmen are mainly concerned with making profits. They live in a competitive world and they have to produce goods at the lowest possible cost. Their profits are determined by the payments made for the raw materials such as copper ore by the Sterilite plant in Tuticorin, cost of land, machinery and labour. The cost to the society from pollution of air and water does not enter into their calculations.
VED 532792 CAIRN CWNQY

 
Delhi HC orders extension of Cairn India contract by 10 years on same terms

2018-06-01 economictimes.indiatimes
Copyright © 2018 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service
532792 CAIRN CWNQY

 
Tax department to sell Cairn Energy#39;s attached shares at #39;appropriate time#39;

2018-05-27 moneycontrol
The Tax Department will sell at an "appropriate time" the shares owned by British firm Cairn Energy plc which were attached following a Rs 10,247-crore tax demand, a senior tax official said.
CNE 532792 CRNZF CAIRN VEDL CWNQY CRNCY

 
India may not accept arbitration orders on Cairn, Vodafone tax cases

2018-05-22 livemint
New Delhi: India may not accept international arbitration orders annulling tax demands on British firms Vodafone Plc and Cairn Energy Plc, a senior official has said, adding that the tax department would continue with recovery actions.
HUWHF CNE 532792 CRNZF CAIRN CWNQY CRNCY

 
Walmart to comply with tax rule on India Flipkart deal, CEO Doug McMillon says

2018-05-10 livemint
New Delhi: Walmart Inc. will comply with any tax demand arising from its purchase of a stake in India’s e-commerce leader, a move that could help the global giant avoid festering litigation that overseas companies such as Vodafone Group Plc face in the South Asian nation.
CNE 532792 VOD VOD VODPF CKHUF CRNZF CKHUY CAIRN CWNQY CRNCY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...